Palvella Therapeutics (PVLA) investor relations material

Strategic vision and pipeline overview

• Focus on developing first-approved therapies for serious rare skin diseases and vascular malformations with high unmet need and low competitive intensity.

• Late-stage pipeline led by QTORIN rapamycin, targeting multiple mTOR-driven diseases, with positive phase III results in microcystic lymphatic malformations (mLM) and ongoing expansion to other indications.

• Fast Track, Breakthrough, and Orphan designations granted for key programs; additional pipeline includes QTORIN pitavastatin for disseminated superficial actinic porokeratosis, with IND-enabling studies nearing completion.

• Plans to announce two more rare disease programs by year-end, aiming for six active programs.

Clinical data and regulatory progress

• Phase III study in mLM showed 95% patient improvement and met all primary and secondary endpoints, supporting a rolling NDA submission targeted for completion by year-end.

• Phase II in cutaneous venous malformations (CVM) showed 73% response rate; phase III design discussions ongoing with FDA, aiming to start the study this year.

• Phase II for angiokeratomas underway, with data expected in the second half of next year; commercial fit aligns with existing infrastructure.

• QTORIN pitavastatin phase II planned to follow a similar design, focusing on both clinician- and patient-reported endpoints.

Commercialization and launch readiness

• Building a seasoned commercial leadership team with experience in orphan drug launches, including hires from successful analogs like Oxervate and Krystal Biotech.

• $230 million raised in Q1, supporting launch preparations, medical affairs deployment, and disease awareness campaigns.

• Plan to hire 40 sales reps ahead of launch, with comprehensive training to ensure readiness upon FDA approval.

• Anticipated launch price for QTORIN rapamycin set between $100,000 and $200,000 per patient per year, based on payer testing and market analogs.